FDA Staff Not Quite Sold on Sotagliflozin for T1D Patients With CKD
MedPage Today) — FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again considers an approval, though now for just a subset with chronic kidney disease (CKD). On Thursday, members…
MedPage Today) — FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again considers an approval, though now for just a subset with chronic kidney disease (CKD).
On Thursday, members…
Read More
About Author
